請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54921完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 胡務亮(Wuh-Liang Hwu) | |
| dc.contributor.author | Yueh-Eo Wu | en |
| dc.contributor.author | 吳月娥 | zh_TW |
| dc.date.accessioned | 2021-06-16T03:41:37Z | - |
| dc.date.available | 2017-03-12 | |
| dc.date.copyright | 2015-03-12 | |
| dc.date.issued | 2015 | |
| dc.date.submitted | 2015-02-12 | |
| dc.identifier.citation | 1. Down, J.L., Observations on an ethnic classification of idiots. 1866. Ment Retard, 1995. 33(1): p. 54-6.
2. Lejeune, J., Gautier,M.,&Turpin,R., Etude des chromosomes somatiques de neu enfants mongoliens CR Acad Sci Paris, 1959. 248: p. 1721-1722. 3. Allen, G., et al., Mongolism. Am J Hum Genet, 1961. 13(4): p. 426. 4. Howard-Jones, N., On the diagnostic term 'Down's disease'. Med Hist, 1979. 23(1): p. 102-4. 5. Lin, S.J., et al., [Anthropometric study on Down syndrome in Taiwan]. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi, 1991. 32(3): p. 158-64. 6. Willard, R.L.N.R.R.M.H.F., Thompson & Thompson Genetics in Medicine. Philadelphia, W.B. Saunders 2001. 7. Jou, H.J., et al., The evolving national birth prevalence of Down syndrome in Taiwan. A study on the impact of second-trimester maternal serum screening. Prenat Diagn, 2005. 25(8): p. 665-70. 8. Dierssen, M., et al., Pitfalls and hopes in Down syndrome therapeutic approaches: in the search for evidence-based treatments. Behav Genet, 2006. 36(3): p. 454-68. 9. Lo, K.C., et al., Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome. Br J Haematol, 2008. 142(6): p. 934-45. 10. Malinge, S., S. Izraeli, and J.D. Crispino, Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood, 2009. 113(12): p. 2619-28. 11. Zwaan, C.M., et al., Acute leukemias in children with Down syndrome. Hematol Oncol Clin North Am, 2010. 24(1): p. 19-34. 12. Massey, G.V., et al., A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood, 2006. 107(12): p. 4606-13. 13. Greene, M.E., et al., Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis, 2003. 31(3): p. 351-6. 20 14. Groet, J., et al., Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet, 2003. 361(9369): p. 1617-20. 15. Gurbuxani, S., P. Vyas, and J.D. Crispino, Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood, 2004. 103(2): p. 399-406. 16. Pine, S.R., et al., Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood, 2007. 110(6): p. 2128-31. 17. Wechsler, J., et al., Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet, 2002. 32(1): p. 148-52. 18. Roy, A., et al., Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. Br J Haematol, 2009. 147(1): p. 3-12. 19. Khan, I., S. Malinge, and J. Crispino, Myeloid leukemia in Down syndrome. Crit Rev Oncog, 2011. 16(1-2): p. 25-36. 20. Xavier, A.C., et al., A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy. PLoS One, 2011. 6(11): p. e27486. 21. Roberts, I., et al., GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood, 2013. 122(24): p. 3908-17. 22. Newton, A., J. Mackay, and M. Crossley, The N-terminal zinc finger of the erythroid transcription factor GATA-1 binds GATC motifs in DNA. J Biol Chem, 2001. 276(38): p. 35794-801. 23. Ferreira, R., et al., GATA1 Function, a Paradigm for Transcription Factors in Hematopoiesis. Molecular and Cellular Biology, 2005. 25(4): p. 1215-1227. 24. Sanger, F. and A.R. Coulson, A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol, 1975. 94(3): p. 441-8. 25. Sanger, F., S. Nicklen, and A.R. Coulson, DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A, 1977. 74(12): p. 5463-7. 21 26. Bartlett, J.M. and D. Stirling, A short history of the polymerase chain reaction. Methods Mol Biol, 2003. 226: p. 3-6. 27. Marziali, A. and M. Akeson, New DNA sequencing methods. Annu Rev Biomed Eng, 2001. 3: p. 195-223. 28. Schuster, S.C., Next-generation sequencing transforms today's biology. Nat Methods, 2008. 5(1): p. 16-8. 29. Tucker, T., M. Marra, and J.M. Friedman, Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet, 2009. 85(2): p. 142-54. 30. Shendure, J. and H. Ji, Next-generation DNA sequencing. Nat Biotechnol, 2008. 26(10): p. 1135-45. 31. Mamanova, L., et al., Target-enrichment strategies for next-generation sequencing. Nat Methods, 2010. 7(2): p. 111-8. 32. Hasle, H., et al., Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML. Leukemia, 2008. 22(7): p. 1428-30. 33. Li, H. and R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics, 2009. 25(14): p. 1754-60. 34. McKenna, A., et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res, 2010. 20(9): p. 1297-303. 35. DePristo, M.A., et al., A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet, 2011. 43(5): p. 491-8. 36. San Lucas, F.A., et al., Integrated annotation and analysis of genetic variants from next-generation sequencing studies with variant tools. Bioinformatics, 2012. 28(3): p. 421-2. 37. Wang, K., M. Li, and H. Hakonarson, ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res, 2010. 38(16): p. e164. 38. Adzhubei, I.A., et al., A method and server for predicting damaging missense mutations. Nat Methods, 2010. 7(4): p. 248-9. 22 39. Ji, H., et al., Next-generation sequencing of dried blood spot specimens: a novel approach to HIV drug-resistance surveillance. Antivir Ther, 2011. 16(6): p. 871-8. 40. Pagnamenta, A.T., et al., Exome sequencing can detect pathogenic mosaic mutations present at low allele frequencies. J Hum Genet, 2012. 57(1): p. 70-2. 41. Gelsi-Boyer, V., et al., Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol, 2012. 5: p. 12. 42. David H. Spencer, H.J.A., y Christina M. Lockwood,* Jacqueline E. Payton,* Philippe Szankasi,z Todd W. Kelley,x and J.D.P. Shashikant Kulkarni, *{ and Eric J. Duncavage*, <Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data..pdf>. Molecular Diagnostics,, 2013. 15: p. 81-93. 43. Rocquain, J., et al., Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 2010. 10: p. 401. 44. Burns, D., et al., Validation of a ligand binding assay using dried blood spot sampling. AAPS J, 2013. 15(1): p. 123-31. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/54921 | - |
| dc.description.abstract | 背景
唐氏症(Down syndrome）是最常見與智能障礙有關的非整倍體(aneuploidy)遺傳疾病，發生率為800分之一。唐氏症患者將會有多重系統徵狀出現，包括身材矮小、智能障礙、畸形、先天性心臟病、先天性胃腸道與泌尿生殖道異常、內分泌功能異常、白血病(Leukemia)及類白血病反應(Leukemoid reaction)。唐氏症患者罹患白血病的機率比一般人高出10到20倍，形成急性巨核細胞白血病(Acute Megakaryoblastic Leukemia；簡稱AMKL)的機率比一般人高出500倍，引發早期造血功能疾病的成因是在體細胞(somatic cell)分裂階段而產生GATA1基因突變(mutation)，造成暫時性骨髓增生疾病(TMD)和急性巨核細胞白血病(AML)。 研究動機 唐氏症白血病大多是與GATA1基因突變有關。由於病人採血不易，因此我們希望能夠建立藉由血片(Dried blood spot；簡稱DBS)萃取DNA來進行GATA1基因定序檢測的方式。 方法 本研究是以血片萃取DNA檢體進行聚合酶鏈鎖反應及Sanger sequencing方法做DNA定序進行變異點檢測，共分析三組病人的GATA1基因是否有突變。第一組為回溯性分析患者24人，其中包含9位有白血球異常(TMD 3人；AMKL 6人)、13位為唐氏症患者但無白血病及2位非唐氏患者但有白血病患者(AMKL 2人)。第二組為前瞻性分析採用本院唐氏確診患者24人，第三組檢體來源為蒙古確診為唐氏症沒有白血病患者39人。 結果 回溯性分析結果呈現24位患者中有8位檢測出GATA1基因突變，結果分別在DS-TMD患者檢出率為100% (3/3)，DS-AMKL患者檢出率為83.3%(5/6)。而前瞻性分析結果顯示本院24位患者當中只有一人年齡約三歲男童檢測出GATA1基因突變，突變偵測率為4.2%。但在蒙古39位患者檢測結果顯示GATA1基因並沒有任何突變(wild type)，突變偵測率為0%。 結論 本研究建立了以血片抽取出的DNA用Sanger定序法針對GATA1基因突變點位檢測的方式。在未來，利用這設計而建立出診斷唐氏症白血病危險因子之高敏感性分子工具，可提供醫師對唐氏症病程的預估及治療做規劃。 | zh_TW |
| dc.description.abstract | Background
Down syndrome (DS) is the most common disorders associated with intelligent disabilities in aneuploidy disorders with an incidence of one in 800 live births. Patients with DS present with symptoms of multi-systemic manifestations, including short stature, mental retardation, malformations, congenital heart disease, congenital gastrointestinal and genitourinary tract abnormalities, endocrine dysfunction, Leukemia and Leukemoid reaction. DS patients had 10-20 times higher risk to develop Leukemia, especially the Acute Megakaryoblastic Leukemia (AMKL) which is even 500 times higher. The cause of Leukemia in DS is considered to be related to the GATA1 mutation, resulting in a temporary myeloproliferative disorders and acute megakaryocytic leukemia (AML). DS and leukemia mostly GATA1 gene mutation. Because of patient blood sampling is difficult, so we hope to establish a method to use blood spots (Dried blood spot; referred DBS) to extract DNA sequencing to detect gene GATA1. Method DNA was extracted from dried blood spots were proceeded into polymerase chain reaction and Sanger sequencing method for GATA1 mutation analysis. This study analyzed three groups of patients. The first group was a retrospective analysis of 24 patients, of whom nine had myeloproliferative disorders (TMD 3 people; AMKL 6 people), 13 DS patients without Leukemia and two AMLK patients but not DS. The second group was prospectively analyzed 24 DS patients in our hospital. The third group of the sample was from 39 Mongolia DS patients without Leukemia. Result Retrospective analysis of 24 patients revealed eight DS patients had positive GATA1 mutations, with the detection rate was 100% (3/3) in DS-TMD; and 83.3% (5/6) in DS-AMLK respectively. The prospective analysis of 24 patients in our hospital showed only one positive for GATA1 mutation in a 3 year-old boy with the detection rate of 4.2%. In 39 Mongolian samples, none was detected to have GATA1 mutation (0%). Conclusion From this study, we established the method to analyze GATA1 mutation from DBS samples. In the future, the utilization of this method could help in the early diagnosis of Leukemia in DS patients, providing an early treatment to achieve better outcome. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-16T03:41:37Z (GMT). No. of bitstreams: 1 ntu-104-P01448012-1.pdf: 842444 bytes, checksum: f2ce2c32a4ac46b0f226bdaf5648e8cd (MD5) Previous issue date: 2015 | en |
| dc.description.tableofcontents | 中文摘要 ................................................ I
Abstract ............................................... III 圖目錄 .................................................VIII 表目錄 .................................................. IX 第一章 研究背景與動機..................................... 1 1.1 唐氏症之歷史 ......................................... 1 1.2 唐氏症之疾病介紹 ..................................... 1 1.3 唐氏症之白血病 ....................................... 2 1.4 GATA1基因突變在唐氏症患者之比例 ...................... 3 1.5 GATA1基因突變造成唐氏症白血病之致病機轉 .............. 4 1.6 GATA1基因突變之基因檢測方式 .......................... 5 1.7 研究目的 ............................................. 6 第二章 研究方法與材料 .................................... 7 2.1 檢體來源 ............................................. 7 2.2 檢體收集 ............................................. 7 2.3 研究方法 ............................................. 8 2.3.1 血片萃取DNA ........................................ 8 2.3.2 聚合酶鏈鎖反應(polymerase chain reaction；簡稱PCR) ..8 2.3.3 洋菜凝膠電泳(Agarose gel electrophoresis) .......... 9 2.3.4 凝膠純化(Gel Extraction) ........................... 9 2.3.5 Sanger sequence分析 ................................ 9 2.3.6 次世代定序分析(Next-Generation Sequencing；簡稱NGS) 10 2.3.7 序列判讀軟體 ...................................... 10 第三章 結果 ............................................. 12 3.1 回溯性分析結果 .......................................12 3.2 前瞻性分析結果 ...................................... 13 3.3 蒙古血片分析結果 .................................... 13 3.4 次世代定序分析(Illumina system)結果 ..................14 第四章 討論 ............................................. 15 4.1 GATA1基因突變在唐氏症的檢出比例 ..................... 15 4.2 突變種類與文獻的比較 .................................16 4.3 血片萃取DNA方法的優缺點 ..............................17 4.4 未來的方向 ...........................................17 第五章 結論.............................................. 18 第六章 參考文獻 ......................................... 19 | |
| dc.language.iso | zh-TW | |
| dc.subject | 濾紙血片 | zh_TW |
| dc.subject | 唐氏症 | zh_TW |
| dc.subject | 白血病 | zh_TW |
| dc.subject | GATA1基因 | zh_TW |
| dc.subject | 基因檢測 | zh_TW |
| dc.subject | Dried blood spot | en |
| dc.subject | Down syndrome | en |
| dc.subject | Leukemia | en |
| dc.subject | GATA1 gene | en |
| dc.subject | Mutation analysis | en |
| dc.title | 建立診斷唐氏症白血病危險因子之高敏感性分子工具 | zh_TW |
| dc.title | The development of high sensitive diagnostic methods for
Leukemia in Down syndrome | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 103-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 李妮鍾(Ni-Chung Lee) | |
| dc.contributor.oralexamcommittee | 陳沛隆(Pei-Lung Chen) | |
| dc.subject.keyword | 唐氏症,白血病,GATA1基因,基因檢測,濾紙血片, | zh_TW |
| dc.subject.keyword | Down syndrome,Leukemia,GATA1 gene,Mutation analysis,Dried blood spot, | en |
| dc.relation.page | 47 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2015-02-12 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
| 顯示於系所單位： | 分子醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-104-1.pdf 未授權公開取用 | 822.7 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。